I wonder how this will affect ABT’s NGF mAb for pain. I’m referring to the recent deal where ABT paid an astounding $170M in up-front cash for a compound still in phase-1 (#msg-43510907).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.